NEU

Neuren Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.

biopharmaceuticals

neurological conditions

ASX

biotechnology

Shorted

short percentage5.52%

reported shorts7M

shares on issue126.640M

Shorted

short percentage

reported short positions

total shares on issue

About

website

neurenpharma.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

At the offices of Lowndes Jordan, Level 15, PWC Tower, 188 Quay Street, AUCKLAND, ., NEW ZEALAND, 1141

Connect

Key Metrics

market cap

$1.85B

p/e ratio12.83

eps$1.14

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

biopharmaceuticals

neurological conditions

ASX

biotechnology

neuroscience

Company Overview

AI-generated company summary

Company History

Neuren Pharmaceuticals was founded with a mission to develop treatments for neurological disorders. Over the years, the company has evolved by focusing on research and development, leading to significant advancements in its product pipeline. Major milestones include the development of DAYBUE® (trofinetide) and NNZ-2591, which target specific syndromes such as Rett Syndrome and Phelan-McDermid Syndrome. Neuren has consistently expanded its research capabilities and partnerships to enhance its market presence.

Competitive Advantages

Neuren Pharmaceuticals has a competitive advantage in its specialized focus on neurological conditions, allowing for targeted and effective treatment development. The company's robust pipeline, including products like DAYBUE® and NNZ-2591, positions it as a leader in addressing rare neurological disorders. Additionally, Neuren's strategic partnerships and collaborations enhance its research capabilities and market reach.

Risk Factors

•Regulatory approval challenges
•High R&D costs
•Market competition

Recent Developments

Last 6 months

In the past six months, Neuren Pharmaceuticals has projected DAYBUE® net sales to reach approximately US$700 million by 2028, highlighting its growth potential. The company has also published results from its NNZ-2591 Phase 2 trial in Neurology Genetics, demonstrating progress in its clinical development programs.

Key People

Leadership team at Neuren Pharmaceuticals

Richard Treagus

Executive Chairman

Richard Treagus has extensive experience in the pharmaceutical industry, having held senior executive roles in both public and private companies. He brings strategic leadership to Neuren Pharmaceuticals.

Patrick Davies

Non-Executive Director

Patrick Davies has a strong background in corporate finance and governance, contributing to Neuren's strategic direction and financial oversight.

Financial Reports

10 reports available

Response to ASX Aware Letter

Financial Reportvia crawler

DAYBUE net sales projected to reach approx US$700m in 2028

Financial Reportvia crawler

NNZ-2591 PMS Phase 2 trial published in Neurology Genetics

Financial Reportvia crawler

Financial Report

Financial Reportvia crawler

Financial Report

Financial Reportvia crawler

Financial Report

Financial Reportvia crawler

Financial Report

Financial Reportvia crawler

Financial Report

Financial Reportvia crawler

Financial Report

Financial Reportvia crawler

Financial Report

Financial Reportvia crawler